In a phase III , open-label , comparative , noninferiority study , 638 subjects receiving de novo kidney transplants were randomized to one of three treatment arms : tacrolimus extended-release ( Astagraf XL ) qd , tacrolimus ( Prograf ) bid , or cyclosporine ( CsA ) bid .